Skip to content

Connecting business. Building understanding. Advancing peace.

Innogen Pharmaceuticals

China–UAE News
Source: Macau Business

Arcera Life Sciences and Innogen Sign Exclusive Licensing Agreement for GLP-1 Therapy

Abu Dhabi-headquartered Arcera Life Sciences and China-based Innogen Pharmaceuticals have entered into an exclusive licensing and commercialization agreement for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy. The partnership covers key international markets including the UAE, Africa, Eastern Europe, and Latin America, with a total potential deal value exceeding US$1 billion.

The UECN Brief

Policy updates, China–UAE business news and industry insights, delivered to your inbox.

Language
Subscriptions

Double opt-in: we send a confirmation link. Unsubscribe at any time. Privacy